BioCentury
ARTICLE | Financial News

Drug delivery company Lyndra raises $55M series B

February 1, 2019 7:52 PM UTC

Lyndra Therapeutics Inc. (Watertown, Mass.) raised $55 million in a series B round to advance compounds delivered via its capsule platform. Polaris Partners led the round and was joined by all other original investors and new investors including HOPU Investments, Gilead Sciences Inc. (NASDAQ:GILD), Invus, the Bill & Melinda Gates Foundation and Orient Life.

Lyndra will use the funds to conduct Phase II trials, for expansion of its Phase I pipeline and manufacturing scale-up...

BCIQ Company Profiles

Lyndra Therapeutics Inc.

BCIQ Target Profiles

NMDA receptor